KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Other Non Operating Income (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 14 years of Other Non Operating Income data on record, last reported at $6.5 million in Q4 2025.

  • For Q4 2025, Other Non Operating Income rose 143.62% year-over-year to $6.5 million; the TTM value through Dec 2025 reached -$7.7 million, up 91.06%, while the annual FY2025 figure was -$7.7 million, 91.06% up from the prior year.
  • Other Non Operating Income reached $6.5 million in Q4 2025 per VRTX's latest filing, up from -$9.8 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $42.4 million in Q3 2021 and bottomed at -$78.1 million in Q2 2022.
  • Average Other Non Operating Income over 5 years is -$13.8 million, with a median of -$12.4 million recorded in 2023.
  • Peak YoY movement for Other Non Operating Income: tumbled 2500.0% in 2024, then surged 157.14% in 2025.
  • A 5-year view of Other Non Operating Income shows it stood at $7.1 million in 2021, then plummeted by 535.03% to -$31.1 million in 2022, then skyrocketed by 68.49% to -$9.8 million in 2023, then tumbled by 52.04% to -$14.9 million in 2024, then surged by 143.62% to $6.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non Operating Income were $6.5 million in Q4 2025, -$9.8 million in Q3 2025, and $13.2 million in Q2 2025.